We are pleased to announce that sotatercept, a new drug for patients diagnosed with pulmonary arterial hypertension (PAH), is now listed on Health Canada's website with the mention “Being reviewed under the Priority Review Policy”.
This milestone follows our advocacy efforts, including a letter urging Health Canada to prioritize the review process for sotatercept. The recognition of sotatercept's potential by regulatory agencies underscores the urgency of bringing this treatment to the Canadian market as soon as possible. Despite the availability of ten medical treatments for PAH in Canada, many patients continue to face serious health challenges.